The Peptide NewsroomPeptide research, industry and supply-chain headlines

Half of Binge Eating Disorder Patients Report Prescribed GLP-1 Use, Researchers Say

Topic card: glp-1

A cross-sectional study reported that roughly half of patients with binge eating disorder, and about one third of people with atypical anorexia nervosa, have used a prescribed glucagon-like peptide-1 receptor agonist. The finding is described in a Lancet Regional Health article arguing that metabolic prescribing now intersects directly with disordered eating.

GLP-1 receptor agonists are the injectable weight and diabetes drugs built on a gut hormone, semaglutide being the best known of them. The authors note there is no established clinical protocol for screening patients for an eating disorder history before one is prescribed, which is the uncomfortable part of that first number.

Two systems that never talk

The article's central point is structural rather than pharmacological: eating disorder services rarely ask about injecting, and harm reduction services rarely ask about restriction, bingeing or purging. Australia is used as the case study, with the authors framing it as a preview for the broader Western Pacific.

Who the online market reaches

Alongside prescribed use, the authors describe non-prescribed semaglutide and newer peptides such as retatrutide circulating as image and performance enhancing drugs. Adolescents are reported to be acquiring them through online marketplaces with no prescription, age verification or clinical oversight.

That is a demographic shift worth sitting with. Harm reduction literature on performance enhancing drugs was built around young men chasing muscularity, while weight loss and leanness marketing now reaches boys and girls through overlapping channels.

The risks nobody is screening for

Injection site infections, needle reuse and sharing, and blood-borne virus transmission are not routinely assessed at eating disorder intake, according to the authors. Harm reduction models, meanwhile, were never designed around severe restriction or purging, so they do not transfer cleanly either.

The article also reports no validated screening instrument for illicit peptide use in young people with disordered eating, and no evidence base for what to do once use is detected. The recommendation is bidirectional screening in both settings, asked directly and without treating disclosure as treatment failure.

Bottom line

This is a commentary on a gap, not a prevalence survey, and the authors are explicit that population-level data is not yet in. What they argue is that waiting for it leaves clinicians working two separate playbooks for one patient.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: glp-1, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.